




STATE MEDICAID P&T COMMITTEE MEETING

Thursday, October 16, 2014

7:00 a.m. to 8:30 a.m.

Cannon Health Building

Room 125



MINUTES

Committee Members Present:

Lisa Hunt, R.Ph.

Kort Delost, R.Ph.

Beth Johnson, R.Ph.

Jameson Rice, Pharm.D.

Roger Martenau, M.D.

Elizabeth Young, Pharm.D.

Committee Members Excused:

Ellie Brownstein, M.D.

Julia Ozbolt, M.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Richard Sorenson, RN

Robyn Seely, Pharm.D.

University of Utah Drug Information Center Staff Present:

Bryan Larsen, PharmD, BCPS

Other Individuals Present:

Meeting conducted by: Lisa Hunt

1. **Review and Approval of September Minutes:** Minutes for September were reviewed. Jameson Rice made a motion to approve the September minutes. Lisa Hunt opened discussion for purposes of clarification on 9.g, page 3. She asked if the Committee's suggestion was for fidaxomicin and telithromycin to not be listed on the PDL, or if they should be listed on the PDL as non-preferred. Lisa Hunt recognized the Committee's September recommendation that the DUR Board review fidaxomicin and telithromycin. Jameson Rice motioned to include fidaxomicin and telithromycin on the PDL after review by the DUR Board. Roger Martenau seconded the motion. All in favor. With that clarification, Jameson Rice motioned to approve the September meeting minutes. Roger Martenau seconded the motion. All in favor.
2. **Housekeeping:**
 - a. PDL Administration: All manufacturers have submitted their 2015 bids and the bids are being reviewed. Last year yielded \$93 million in rebates, in part because of the Committee's work.
 - b. Lisa Hunt reminded everyone to sign in and to take an agenda.

3. **Drug Utilization Review (DUR) Board update:** Robyn Seely reported that the DUR board reviewed Tamiflu and Relenza in the last meeting (10/09/2014), in which she informed the Board to the Department Director's instructions to remove all PA criteria from Tamiflu and Relenza for the foreseeable future. Utah Medicaid's Office of the Inspector General presented information regarding physician-administered opiates. November's meeting will consist of a discussion on rheumatoid arthritis.
4. **Aminoglycosides:** Bryan Larsen presented a review of the aminoglycosides. He presented peer-reviewed research regarding the safety and efficacy of each agent, disease-state treatment guidelines Utah Medicaid utilization data.
5. **Public Comments:** None
6. **Committee discussion:**
 - a. Lisa Hunt mentioned other states' coverage of the aminoglycosides. Most states divide them into ophthalmic and oral categories.
 - b. The Committee discussed various ways to divide the class based upon route of administration, including over-the-counter preparations.
 - c. Jameson Rice asked about adverse drug reactions. Bryan Larsen said that most toxicity comes with injectable dosage forms, and that control of peaks and troughs is key.
 - d. Roger Martenau motioned to divide the agents into four categories: Oral, Injectable, Topical (including ophthalmic, otic and GU [neomycin for bladder irrigation, see item i below]) and Inhaled. Jameson Rice seconded. All in favor.
 - e. Injectable Agents: Kort observed that none of the agents are particularly safe, and Roger Martenau motioned that all of the injectable aminoglycosides are equally safe and effective for their intended purpose(s). Beth Young seconded.
 - f. Kort Delost asked for any public comment; there was none.
 - g. All in favor of the motion in item e above.
 - h. Topical Agents: Jameson Rice observed that many of the topical aminoglycosides are in combination with other agents. Lisa Hunt said that it is Utah Medicaid's responsibility to research combination products, single agent products, and pricing. Roger Martenau motioned that all of the topical aminoglycosides are equally safe and effective for inclusion on the PDL. Beth Young seconded. All in favor.
 - i. Oral Agent: Erythromycin is the only oral agent. The Committee revisited neomycin for bladder irrigation (see item d above). Kort Delost motioned that, because of their unique indications, erythromycin and neomycin be included on the PDL. Jameson Rice seconded. All in favor.
 - j. Inhaled Agents: Lisa Hunt noted other states' coverage of tobramycin. Roger Martenau motioned that tobramycin nebulized solution is safe and effective for patients for approved uses and be considered for inclusion on the PDL. Bryan Larsen observed that the Tobi Podhaler is an inhaled powder. Kort Delost seconded. All in favor.

7. Meeting Adjourned

8. Next meeting is scheduled for November 20, 2014. Amebicide anti-infective agents will be discussed.
9. Lisa Hunt requested that Committee members inform her of their anticipated presence of absence so that a quorum is ensured at each meeting.

Minutes prepared by Robyn Seely

Recording available upon request, send email to medicaidpharmacy@utah.gov